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Poster Session I S209cells/kg. The mean peripheral CD34 count prior to the use of P was
3.3/ul, and increased to 8.8/ul after its use.
Conclusion: Our limited single-center outcomes data suggests that
the addition of P as a salvage agent may improve mobilization out-
comes in poor mobilizers. Further evaluation is needed to combine
P with CY1G in terms of optimal timing and dosing of chemother-
apy utilized.150
SUCCESSFUL AUTOLOGOUS STEM CELL TRANSPLANT AFTER 21 YEARS
OF CRYOPRESERVATION
Cherry, M.A.1, Kern, W.2, Wageman, B.2, Epstein, R.1, O’neal, C.1,
Kratochvill, K.2, Selby, G.1, Holter, J.1 1OklahomaUniversity Health Sci-
ences Center, Oklahoma City, OK; 2Oklahoma University Health Sciences
Center, Oklahoma City, OK
Introduction: Successful transplantation of cryopreserved hemato-
poietic stem cells can be regularly achieved provided sufficient num-
bers of cells are administered. The duration of hematopoietic stem
cell viability is unclear. Evidence of autologous repopulation has
been seen at 14 years after bone marrow transplant and 12 years after
peripheral stem cell transplant. We report a successful autologus
transplantation 21 y after cryopreservation.
Case: The patient is 43 year old man found to have follicular lym-
phoma with bone marrow involvement in 1989 at age 22. He
achieved complete remission after treatment with two cycles of
Chorambucil. Bone marrow (BM) procurement and cryopreserva-
tion was performed at that time for possible subsequent infusion.
The procured BM consisted of a total cell count of 1.21  108
cells/per kg body weight with a total volume of 354 ml. Equal parts
of 20%DMSOwere combined with marrow to a final concentration
of 10% DMSO. The BM was stored in the liquid phase of nitrogen
until date of infusion 21 years later. Our patient relapsed in 1996, and
underwent treatment in 2006 with six cycles of Fludarabine and Rit-
uximab, achieving a complete remission. He continued Rituximab
maintenance and then developped pancytopenia. Work-up con-
firmed MDS with 5q- and t(6q21;17p13) in 20/20 cells by karyotype
analysis. Assessment of previously cryopreserved marrow was under-
taken showing no evidence of cytogenetic or histological changes.
The patient was prepared with Busulfan IV at 0.8/kg q 6 hours 
4 days and Cyclophosphamide 60mg/kg IV  2 days. The BM was
infused and samples from the infused marrow showed 65-75% via-
bility by Tryptan blue assay. White cell engraftment occurred on
day 17 and platelet reached 20,000/uL by day 30.
Follow-up 2months post transplant revealedWBCof 2.6 x103/uL
with ANC 1.5103/uL, Hgb 9.8 gr/dl and platelets of 43,000/uL.
FISH analysis for 5q performed showed 85/200 cells positive for
5q-. BM biopsy confirmed dysplastic features consistent with his
pre-transplant BM.
Our case illustrates that even in the setting of marginal numbers of
infused marrow components and after prolonged cryopreservation,
repopulation can readily occur. To our knowledge, this is the oldest
successful cryopreserved autologous bone transplant at 21 years post
preservation. As novel uses of stem cells advance, optimal storage of
various cellular components is necessary. This should be further
investigated on a larger scale in the future.CLINICAL CELLULAR THERAPY151
TUMOR-INFILTRATING LYMPHOCYTES ARE PRESENT IN CANCER
RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION (ALLOHSCT), OF DONOR ORIGIN, DISTINCT FROM PERIPHERAL
BLOOD DONOR LYMPHOCYTES AND EXHIBIT EFFECTOR FUNCTION
WITH CD3/CD28 COSTIMULATION EX-VIVO
Hardy, N.M., Hakim, F.T., Fellowes, V.S., Rose, J.J., Gress, R.E.,
Bishop, M.R. National Cancer Institute, Bethesda, MD
We theorized that in patients with persistent or relapsed cancer
following alloHSCT, tumor would be a source of tumor-reactivedonor T lymphocytes that could be expanded ex vivo to provide
a potent T cell therapy.We recently reported our initial clinical re-
sults demonstrating feasibility, safety and biologic activity of this
approach in patients with refractory B cell tumor relapse after al-
loHSCT (ASH 2010). We report here the characterization of the
initial tumor infiltrate as compared to circulating T cell popula-
tions, and as compared to expanded products from tumor and
blood. We determined that tumor-infiltrating donor T cells (con-
firmed by chimerism assays) differed from peripheral donor T cell
populations in individual patients in terms of T cell frequency,
na€ıve/memory phenotype, ratio of CD4:CD8 cells and frequencies
of effector and regulatory T cell populations. Following a-CD3/
CD28 antibody-coated bead expansion with low dose IL-2,
PCR-based chimerism assessment of products demonstrated that
the costimulated lymphocytes were of donor origin; by flow, prod-
ucts were greater than 95% CD31 T cells. CD41 T cells usually
predominated, but there was significant patient variation in expan-
sions from both tumor infiltrates and blood. Both expanded tumor
and blood products demonstrated increased expression of markers
of activation and effector function (CD4: CD40L; CD8: CD137,
perforin, NKG2D). The proportion of FoxP31 Treg cells de-
clined and IFN-producing TBet1 Th1/Tc1 effectors became the
dominant T cell population. While the percentage of cells express-
ing CD27 and CD28 declined proportionate to the duration of cul-
ture, their expression was retained in a significant proportion of
cells after our typical 12-day culture. Our findings support the hy-
pothesis that, after allotransplant, donor lymphocytes can be iden-
tified in residual/progressing tumor, and appear to be distinct from
circulating T cell populations. Furthermore, these tumor-infiltrat-
ing T cells can be effectively expanded, even from minor popula-
tions, to become T-Bet1 T effectors, plausibly circumventing
a mechanism of GVL resistance. Costimulated tumor-derived do-
nor lymphocytes may be a therapeutic option for patients without
a source of, or who have not responded to, donor lymphocyte in-
fusion for disease progression after alloHSCT.152
NON-EXPANDED PR1-SPECIFIC CTL SORT-PURIFIED DIRECTLY FROM
CORD BLOOD LYMPHOCYTES DEPLETE HUMAN AML IN VIVO
St. John, L.S., He, H., Quintanilla, K., Ma, Q., Shpall, E.J.,
Alatrash, G., Clise-Dwyer, K., Molldrem, J.J. The University of Texas
M.D. Anderson Cancer Center, Houston, TX
Relapse remains a significant problem following allogeneic stem
cell transplantation (SCT) for AML. Adoptive transfer of leukemia-
specific cytotoxic T lymphocytes (CTL), such as PR1-specific
CTL, might be used to treat persistent leukemia after SCT by en-
hancing graft versus leukemia (GVL) while minimizing graft versus
host disease (GVHD).A limitationof this approach is the limitedper-
sistence of adoptively transferred T cells in the recipient, due in part
to the lengthy ex vivo expansion of low frequency cells necessary to
obtain a sufficient cell number.We chose to study PR1-CTLderived
fromumbilical cord blood (UCB)based onour observation thatUCB
PR1-CTL are increased 100- to 1,000-fold compared to adult pe-
ripheral blood (PB), suggesting UCB might be a rich source of
PR1-CTL. Because UCB is associated with a decreased risk of
GVHD, in part because of the predominance of naive T cells, it
may also be a preferred platform to transfer GVL with minimal risk
of GVHD. We found the frequency of PR1-CTL in UCB to be
0.007 to 0.345% (mean 0.117%; n 5 57) of CD81 cells compared
with a frequency of\0.001% in healthy adult PB. Therefore, we hy-
pothesized that a sufficient number of PR1-CTL fromUCBcould be
obtained by PR1/HLA-A2 tetramer-based cell sorting and infused
without further expansion to mediate GVL. To test this, CD81 T
cells fromHLA-A21UCB units were first enriched via whole blood
negative immunodensity separation. Enriched cells were sorted (.
98% purity) into PR1-CTL and PR1-CTL-depleted CD81 cells
(PDC) and briefly activated ex vivo for 48 hours with soluble anti-
CD3/anti-CD281 IL-2.After 48 hours, PR1-CTLspecifically lysed
PR1-pulsed T2 cells although 95% of PR1-CTL and PDC retained
a CCR71CD45RA1 naive phenotype. Next, 1  104 cells were in-
fused into NOD/SCIDmice engrafted for 7 days with 2-4 106 hu-
man AML blasts. Three separate experiments were performed. Two
S210 Poster Session Iweeks after adoptive transfer, AML in bone marrow (BM) of
PR1-CTL treated mice decreased 27% (range 21%-32%; p \
0.02) compared to untreated mice, and by 23% (range 4%-47%; p
5 NS) compared to mice receiving PDC. Moreover, AML in the
PB of PR1-CTL treated mice decreased 47% (range 30%-61%, p
\ 0.04) compared to untreated mice, and by 58% (range 48%-
68%; p\0.01) compared to mice receiving PDC. These data justify
clinical studies to determine whether PR1-CTL isolated directly
from UCB can be used to enhance GVL without increased GVHD.153
ANTIGEN PRESENTING CELL-MEDIATED EX VIVO EXPANSION OF
HUMAN UMBILICAL CORD BLOOD CELLS YIELDS SIGNIFICANT EXPAN-
SION OF NATURAL KILLER CELLS WITH ANTI-MYELOMA ACTIVITY
Shah, N.1, Ku, S.2, Xing, D.1, Lee, D.3, Cooper, L.3, Tzou, B.2,
Decker, W.1, Li, S.1, Robinson, S.1, Yang, H.1, Parmar, S.1, Tung, S.1,
Bollard, C.2, Shpall, E.J.1 1M.D. Anderson Cancer Center, Houston,
TX; 2Baylor College of Medicine, Houston, TX; 3M.D. Anderson Cancer
Center, Houston, TX
Background: Allogeneic natural killer (NK) cells are active in vari-
ous hematologic malignancies and may have an important role in
multiple myeloma (MM). Umbilical cord blood (UCB) is a potential
source for allogeneic NK cells and ex vivo expanded UCB-derived
NK (UCB-NK) cells demonstrate activity comparable to that of pe-
ripheral blood-derived NK cells. Here we demonstrate the ability to
expand fresh and frozen UCB-NK cells to clinical grade by novel
techniques using artificial antigen presenting feeder cells modified
to express IL-21 (‘‘K562-cl9-mIL21’’) or IL-15 (‘‘K562-mb-15-
41BBL’’). TheseUCB-NK cells demonstrate appropriate phenotype
and are active against a variety of MM cell lines.
Methods: UCB-NK cells were expanded from 1) fresh or 2) frozen
cord blood units. 1) Fresh cord blood mononuclear cells (CBMCs)
were cultured in 10% human serum albumin media with IL-2 (500
IU/ml) and irradiated K562-cl9-mIL21 feeder cells (2:1 feeder:
CBMCratio) for 21 days.Thereafter, cells were subjected toCD3-im-
munomagnetic depletion. 2) Frozen CBMC’s were grown in a gas
permeable culture flask with IL-2 (100 IU/ml) and irradiated K562-
mb-15-41BBL feeder cells (2:1 feeder: CBMC ratio). Cells were
CD3-depleted on day 7, replated with the same conditions and grown
until day 14. CD3-negative cells were then used as effector cells in
functional assays. Flow cytometry was used to confirmNK cell purity
(C561/CD3- cells) and a standard chromium-51 assay was performed
to determine NK cell cytotoxicity. Targets included K562 cells and
MM cell lines RPMI 8226, ARP-1 and U266.
Results:Expansion of fresh and frozenCBMCs yielded a. 2000 and
. 200 fold expansion ofNKcells, respectively, compared with only 47
fold expansion of fresh CD56-selected cells cultured with IL-2 alone.
After CD3 depletion, fresh and frozen-derived UCB-NK cultures
were comprised of 92% and 94% CD561/CD3- cells respectively.
APC-expanded UCB-NK cells from fresh and frozen cords demon-
strated cytotoxicity against the classic NK cell target K562 as well as
MM cell lines RPMI 8226, ARP-1 and U266.
Conclusions: UCB-NK cells can be expanded ex vivo to clinically
relevant doses for allogeneic NK cell therapy via co-culture with
K562-cl9-mIL21 and K562-mb-15-41BBL feeder cells. Expanded
UCB-NK cells are cytotoxic to K562 cells and various myeloma cell
lines.Further studyof freshand frozen-derivedUCB-NKcells asanad-
junct therapy in stem cell transplantation for myeloma is warranted.154
TRANSFER OF SPECIFIC CELLULAR AND HUMORAL ANTI-TUMOR IMMU-
NITY AFTER STEM CELL TRANSPLANT (SCT) BY VACCINATING STAGE IV
BREAST CANCER PATIENTS WITH Her2/Neu TARGETED T CELLS AND
TRANSFERRING IMMUNE T CELLS INTO THE PATIENTS AFTER SCT
Thakur, A.1, Al-Kadhimi, Z.1, Paul, E.1, Skuba, C.2, Davol, P.3,
Steele, P.1, Rathore, R.3, Ayash, L.1, Abidi, M.1, Uberti, J.1,
Ratanatharathorn, V.1, Lum, L.G.1 1Karmanos Cancer Institute, Detroit,
MI; 2College Veterinary Medicine, East Lansing, MI; 3Roger William
Medical Center, Providence, RIWomen with stage IV metastatic breast cancer (BrCa) have lim-
ited treatment options. Innovative treatment strategies are needed
to improve anti-tumor responses. We have recently shown that spe-
cific T cell immunity can be induced in patients by ‘‘vaccinating’’ the
patients (pts) with infusions of anti-CD3  anti-Her2/neu bispecific
antibody (Her2Bi) armed activated T cells (aATC). This study inves-
tigated whether memory cytotoxic T lymphocytes (CTL) and anti-
body (Ab) directed at BrCa antigens can be transferred into
patients after SCT by evaluating the cytotoxic and Ab responses after
aATC infusions prior to SCT and after SCT. After infusions of
aATC, peripheral blood lymphocytes (PBL) exhibited high levels
of cytotoxicity directed at SK-BR-3 breast cancer cells and high se-
rum levels of Th1 cytokines and IL-12. Three weeks after aATC in-
fusions, ATC were expanded from the second leukopheresis and
cryopreserved for re-infusion after SCT. The expanded ATC from
6 patients at an E:T ratio of 25:1 exhibited cytotoxicity ranging
from 3.7-25.8 (mean13.6%) directed at the SK-BR-3. After SCT,
pts received multiple infusions with a mean total of 54x109 ATC
(range 16-110  109). Cytotoxicity ranged from 4.7 to 70 % from
2 weeks to 12 months post SCT. We tested PBL for the transfer
of humoral immunity after SCT by co-culturing PBL with or with-
out SK-BR-3 tumor cells before IT, mid-IT, 1 month post-IT, pre
and post SCT for in vitro specific anti-SK-BR-3 Ab synthesis.
Anti-SK-BR-3 Abs detected in the culture supernatants by ELISA
ranged from 15 to 40 ng/ml of Abs prior to IT, 150-220 ng/ml
mid-IT and remained high between 70-95 ng/ml at 1 month post-
IT. PBL after SCT showed gradual increases in in vitro Ab synthesis
ranging from 0-10 ng at 1-month post SCT to 70-90 ng by six-
month post SCT upon stimulation with tumor cells. Serum antitu-
mor Ab levels directed at SK-BR-3 increased from 2-4 mg to 10-12
mg post IT and between 6-9 mg after SCT. No dose-limiting
toxicities, delays in engraftment, and life-threatening infections
were observed. These data show that transfer of pre-immunized
ATC and T cells in the stem cell product enhance tumor specific cy-
totoxicity after HDC and PBSCT for breast cancer. Data suggest
that both cellular and Ab responses can be transferred and provide
an anti-tumor immune response early after SCT. This ‘‘vaccinate’’
and ‘‘boost’’ proof-of-principal strategy may be used to design
protocols to enhance anti-tumor activity.155
IMPROVED POST-THAW STABILITY VALIDATION OF PERIPHERAL BLOOD
CELL PRODUCTS UTILIZING THE INTRACELLULAR-LIKE CryoStor
CRYOPRESERVATION SOLUTION, AND PRELIMINARY RESULTS OF
CLINICAL APPLICATION
Fritsch, G.1, Witt, V.1, Matthes, S.1, Dworzak, M.1, Artwohl, M.1,
Clarke, D.2, Mathew, A.J.2 1St. Anna Kinderkrebsforschung, Vienna,
Austria; 2BioLife Solutions, Inc., Bothell, WA
Collection and cryopreservation of autologous stem cells is a rou-
tine procedure in a variety of malignant diseases. Further, improved
stability of cell products is critical to the development of cell and tis-
sue based therapies as part of the growth in regenerative medicine. A
growing body of evidence indicates that one key method for im-
proved cryopreservation efficacy is the utilization of a hyperos-
motic/intracellular-like cryopreservation media, as opposed to the
traditional use of an isotonic/extracellular-like media such as saline
as the vehicle for the cryoprotectant. In this evaluation of cryopres-
ervationmethods for clinical application, cell samples from apheresis
products were cryopreserved in a conventional isotonic-based freeze
media (CFM; 20% DMSO, 10% human plasma derivate in Ringer
solution) or intracellular-like CryoStor CS10 (CS10; 10% DMSO,
serum-free and protein-free). Immediately after thawing, the recov-
ery ofWBCwas 50.76 14.4% forCFMversus 706 11.6% forCS10
(p\0.001), and that of CD341 cells 81.86 36.1% forCFMand 101
6 16.4% for CS10 (p\ 0.05). In CFM, 20 to 60 min after thawing
there was a dramatic loss in cell viability (-40% to -90%), up to com-
plete clotting in 3/10 samples. By contrast, cells remained viable up
to 60 min after thawing in CS10, and no clotting occurred. Because
of these positive validation results, cryopreservation in the intracel-
lular-like CryoStor CS10 was translated to clinical application for
treatment of hematological malignancies. To date, seven patients
have received autologous stem cells cryopreserved in CS10.
